• Intellia Therapeutics Inc NTLA.OQ reported a quarterly adjusted loss of $1.27​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.46. The mean expectation of twenty five analysts for the quarter was for a loss of $1.33 per share. Wall Street expected results to range from $-1.61 to -86 cents per share.

• Revenue rose 771.6% to $12.87 million from a year ago; analysts expected $8.53 million.

• Intellia Therapeutics Inc's reported EPS for the quarter was a loss of $1.27​.

• The company reported a quarterly loss of $128.9 million.

• Intellia Therapeutics Inc shares had fallen by 7.4% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 7 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Intellia Therapeutics Inc is $46.00

This summary was machine generated from LSEG data February 27 at 03:07 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)